Defined Cellular Reprogramming of Androgen Receptor-active Prostate Cancer to Neuroendocrine Prostate Cancer

Overview

Journal bioRxiv

Date 2025 Mar 3

PMID 40027790

Authors

Shan Li

Kai Song

Huiyun Sun

Yong Tao

Arthur Huang

Vipul Bhatia

Brian Hanratty

Radhika A Patel

Henry W Long

Colm Morrissey

Michael C Haffner

Peter S Nelson

Thomas G Graeber

John K Lee

Affiliations

Soon will be listed here.

Abstract

Neuroendocrine prostate cancer (NEPC) arises primarily through neuroendocrine transdifferentiation (NEtD) as an adaptive mechanism of therapeutic resistance. Models to define the functional effects of putative drivers of this process on androgen receptor (AR) signaling and NE cancer lineage programs are lacking. We adapted a genetically defined strategy from the field of cellular reprogramming to directly convert AR-active prostate cancer (ARPC) to AR-independent NEPC using candidate factors. We delineated critical roles of the pioneer factors ASCL1 and NeuroD1 in NEtD and uncovered their abilities to silence AR expression and signaling by remodeling chromatin at the somatically acquired AR enhancer and global AR binding sites with enhancer activity. We also elucidated the dynamic temporal changes in the transcriptomic and epigenomic landscapes of cells undergoing acute lineage conversion from ARPC to NEPC which should inform future therapeutic development. Further, we distinguished the activities of ASCL1 and NeuroD1 from the inactivation of RE-1 silencing transcription factor (REST), a master suppressor of a major neuronal gene program, in establishing a NEPC lineage state and in modulating the expression of genes associated with major histocompatibility complex class I (MHC I) antigen processing and presentation. These findings provide important, clinically relevant insights into the biological processes driving NEtD of prostate cancer.

References

Abida W, Cheng M, Armenia J, Middha S, Autio K, Vargas H . Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. JAMA Oncol. 2018; 5(4):471-478. PMC: 6459218. DOI: 10.1001/jamaoncol.2018.5801. View

Burr M, Sparbier C, Chan K, Chan Y, Kersbergen A, Lam E . An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer. Cancer Cell. 2019; 36(4):385-401.e8. PMC: 6876280. DOI: 10.1016/j.ccell.2019.08.008. View

Hu R, Dunn T, Wei S, Isharwal S, Veltri R, Humphreys E . Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009; 69(1):16-22. PMC: 2614301. DOI: 10.1158/0008-5472.CAN-08-2764. View

Watson P, Arora V, Sawyers C . Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015; 15(12):701-11. PMC: 4771416. DOI: 10.1038/nrc4016. View

Qiu X, Mao Q, Tang Y, Wang L, Chawla R, Pliner H . Reversed graph embedding resolves complex single-cell trajectories. Nat Methods. 2017; 14(10):979-982. PMC: 5764547. DOI: 10.1038/nmeth.4402. View

Akamatsu S, Wyatt A, Lin D, Lysakowski S, Zhang F, Kim S . The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer. Cell Rep. 2015; 12(6):922-36. DOI: 10.1016/j.celrep.2015.07.012. View

Baine M, Hsieh M, Lai W, Egger J, Jungbluth A, Daneshbod Y . SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization. J Thorac Oncol. 2020; 15(12):1823-1835. PMC: 8362797. DOI: 10.1016/j.jtho.2020.09.009. View

Yu G, Wang L, He Q . ChIPseeker: an R/Bioconductor package for ChIP peak annotation, comparison and visualization. Bioinformatics. 2015; 31(14):2382-3. DOI: 10.1093/bioinformatics/btv145. View

Tsoi J, Robert L, Paraiso K, Galvan C, Sheu K, Lay J . Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress. Cancer Cell. 2018; 33(5):890-904.e5. PMC: 5953834. DOI: 10.1016/j.ccell.2018.03.017. View

10.

Jouravel N, Sablin E, Arnold L, Guy R, Fletterick R . Interaction between the androgen receptor and a segment of its corepressor SHP. Acta Crystallogr D Biol Crystallogr. 2007; 63(Pt 11):1198-200. DOI: 10.1107/S0907444907045702. View

11.

Babos K, Galloway K, Kisler K, Zitting M, Li Y, Shi Y . Mitigating Antagonism between Transcription and Proliferation Allows Near-Deterministic Cellular Reprogramming. Cell Stem Cell. 2019; 25(4):486-500.e9. PMC: 6778044. DOI: 10.1016/j.stem.2019.08.005. View

12.

Viswanathan S, Ha G, Hoff A, Wala J, Carrot-Zhang J, Whelan C . Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing. Cell. 2018; 174(2):433-447.e19. PMC: 6046279. DOI: 10.1016/j.cell.2018.05.036. View

13.

Han M, Li F, Zhang Y, Dai P, He J, Li Y . FOXA2 drives lineage plasticity and KIT pathway activation in neuroendocrine prostate cancer. Cancer Cell. 2022; 40(11):1306-1323.e8. DOI: 10.1016/j.ccell.2022.10.011. View

14.

Stuart T, Srivastava A, Madad S, Lareau C, Satija R . Single-cell chromatin state analysis with Signac. Nat Methods. 2021; 18(11):1333-1341. PMC: 9255697. DOI: 10.1038/s41592-021-01282-5. View

15.

Epstein J, Amin M, Beltran H, Lotan T, Mosquera J, Reuter V . Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol. 2014; 38(6):756-67. PMC: 4112087. DOI: 10.1097/PAS.0000000000000208. View

16.

Raposo A, Vasconcelos F, Drechsel D, Marie C, Johnston C, Dolle D . Ascl1 Coordinately Regulates Gene Expression and the Chromatin Landscape during Neurogenesis. Cell Rep. 2015; 10(9):1544-1556. PMC: 5383937. DOI: 10.1016/j.celrep.2015.02.025. View

17.

Ross-Innes C, Stark R, Teschendorff A, Holmes K, Ali H, Dunning M . Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature. 2012; 481(7381):389-93. PMC: 3272464. DOI: 10.1038/nature10730. View

18.

Borromeo M, Savage T, Kollipara R, He M, Augustyn A, Osborne J . ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs. Cell Rep. 2016; 16(5):1259-1272. PMC: 4972690. DOI: 10.1016/j.celrep.2016.06.081. View

19.

Ku S, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich Z . Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science. 2017; 355(6320):78-83. PMC: 5367887. DOI: 10.1126/science.aah4199. View

20.

Lin D, Wyatt A, Xue H, Wang Y, Dong X, Haegert A . High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res. 2013; 74(4):1272-83. DOI: 10.1158/0008-5472.CAN-13-2921-T. View